• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Schizophrenia research and treatment >Very Low-Dose Risperidone in First-Episode Psychosis: A Safe andEffective Way to Initiate Treatment
【24h】

Very Low-Dose Risperidone in First-Episode Psychosis: A Safe andEffective Way to Initiate Treatment

机译：首次发作性精神病中的超低剂量利培酮：一种安全有效的治疗方法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients experiencing a first psychotic episode have high rates of extrapyramidal symptoms (EPSs) when treated with the doses of neuroleptics used in multiepisode or chronic schizophrenia. There is some evidence that lower doses may be equally, if not more, effective but less toxic in this population. Here, we report the results of a biphasic open label trial designed to assess the efficacy, safety, and tolerability of low-dose (2–4 mg/day) risperidone treatment in a group of 96 first-episode nonaffective psychosis patients. At the end of the trial, 62% of patients met the response criteria although approximately 80% had achieved a response at some time during the study. Reports of EPS remained low, and there were no dystonic reactions. We conclude that even at a dose of 2 mg/day, risperidone was highly effective in reducing acute symptomatology in a real world sample of young first-episode psychosis patients.
机译：第一次精神病发作的患者接受多表或慢性精神分裂症用的抗精神病药治疗时，锥体外系症状（EPS）发生率较高。有证据表明，在该人群中，较低剂量可能同样有效，但毒性较小。在这里，我们报道了一项双相开放标签试验的结果，该试验旨在评估96例首发非情感性精神病患者中低剂量（2-4 mg /天）利培酮的疗效，安全性和耐受性。在试验结束时，有62％的患者达到了缓解标准，尽管大约80％的患者在研究期间的某个时间达到了缓解。每股收益的报告仍然很低，没有肌张力异常反应。我们得出的结论是，即使在每天2 mg的剂量下，利培酮在减少年轻的首发精神病患者的真实世界样本中也能有效降低急性症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号